Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia-Reference-Cited by-同舟云学术

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia

Published:2018-08-17 Issue:16 Volume:2 Page:2063-2071
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Ball Brian¹,Komrokji Rami S.²,Adès Lionel³,Sekeres Mikkael A.⁴,DeZern Amy E.⁵,Pleyer Lisa⁶,Vey Norbert⁷,Almeida Antonio⁸,Germing Ulrich⁹,Cluzeau Thomas¹⁰,Platzbecker Uwe¹¹,Gore Steven D.¹²,Fenaux Pierre³,Prebet Thomas¹²

Affiliation:

1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;

2. Malignant Hematology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;

3. Clinical Hematology, Centre Hospitalier Universitaire Saint-Louis and Paris 7 University, Paris, France;

4. Leukemia Program, Cleveland Clinic, Cleveland, OH;

5. Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD;

6. Department of Hematology and Medical Oncology, Paracelsus Medical University Hospital Salzburg, Salzburg, Austria;

7. Institut Paoli-Calmettes, Marseille, France;

8. Serviço de Hematologia, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal;

9. Department of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany;

10. Centre Hospitalier Universitaire Nice, Nice, France;

11. Universitätsklinikum Carl Gustav Carus, Dresden, Germany; and

12. Hematology Department, Yale New Haven Hospital, New Haven, CT

Abstract

Key Points Induction led to response in 41% and 32%, survival of 10.8 and 6 months, and transplant in 40% and 42% of responders in MDS and AML. Treatment with high-dose cytarabine improved response rates in MDS and an anthracycline-containing regimen increased survival in AML.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/2/16/2063/881497/advances015529.pdf

Reference43 articles.

1. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B;Silverman;J Clin Oncol,2002

2. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study;Kantarjian;Cancer,2006

3. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol,2009

4. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy;Lübbert;Haematologica,2012

5. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts;Dombret;Blood,2015

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety, Efficacy, and Predictive Factors of Venetoclax-Based Regimens in Elderly Acute Myeloid Leukemia Patients: A Meta-Analysis;Clinical Lymphoma Myeloma and Leukemia;2024-08

2. Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy;Leukemia & Lymphoma;2024-03-05

3. What value do cell cycle inhibitors have in the treatment of myelodysplastic syndrome?;Expert Opinion on Pharmacotherapy;2023-04-23

4. What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach;Cancers;2023-04-12

5. Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia;International Journal of Molecular Sciences;2023-03-06